220 Stocks to Sell Today
Free Report for Zacks.com
Visitors Only

Overall, Zacks Rank #5 Strong Sells perform 6X worse than the market. Are any of these portfolio killers lurking among the stocks you're holding or considering? Find out today for free.


No cost, no obligation to buy anything ever.
Privacy Policy
Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/19/2013

Company Name Symbol %Change
SONIC FOUNDR SOFO
4.40%
SUPPORTCOM I SPRT
3.75%
UNISYS CORP UIS
3.31%
SHORETEL INC SHOR
3.22%
GREEN MOUNTA GMCR
3.13%

Accenture Wins Airedale Deal

by Zacks Equity Research

September 24, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

After winning a deal from the Brazilian communication service provider Oi, Accenture Plc. (ACN - Snapshot Report) has now entered into a three-year agreement with the Airedale NHS Foundation Trust.

Accenture will provide the IT infrastructure that will make 1.1 million patient records available to Airedale clinicians. The easy accessibility of data will increase the efficiency of Airedale’s healthcare system, thereby improving patient care.

In the process, Accenture will be deploying TPP’s SystmOne solution, which targets the entire hospital system, including the administration system, out-patient care, emergency care management, bed management, e-prescriptions and e-discharge. Each of these systems is available as a module, facilitating its deployment. Accenture has stated that all except the last two modules will be set up immediately, with the last two scheduled for 2013.

It is encouraging to note Accenture’s progress in the healthcare segment, since U.S. health reforms are pushing many healthcare providers toward the electronic health records (EHR) segment. This is likely to be positive driver for the segment in the near to medium term and Accenture, along with other technology companies like Hewlett Packard Company (HPQ - Analyst Report) and Dell Inc. (DELL - Analyst Report) is likely to benefit.

Apart from the consulting business, Accenture witnessed strength in its Outsourcing domain during the third quarter of 2012, which resulted in the seventh consecutive quarter of double-digit growth. Moreover, the company is also seeing an expansion in the European market as outsourcing deals increased in the region. Outsourcing business is gradually improving, which is expected to continue in the near future.

Accenture has been instrumental in providing technological services not only for companies in the field of telecommunication and supply-chain management, but also for companies coming from a completely different industry like drug manufacturing and healthcare.

We are encouraged by the steady flow of new businesses and believe that the trend will continue. However, increasing competition from IBM Corp. (IBM) and a cautious spending environment may curb its growth prospects to some extent. This apart, low business growth in Europe is also acting as a dampener.

The company has a Zacks #3 Rank, implying a short-term Hold rating.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.